Advanced Therapies in the Cold Chain

Advanced Therapies in the Cold Chain

Advanced therapies do not operate within traditional cold chain systems. Temperature control, timelines, and regulatory scrutiny have fundamentally changed.

The systems that worked for conventional products were built for stability, scale, and flexibility. They cannot absorb the constraints that define advanced therapy logistics.

When product viability is measured in hours, materials are patient-specific, and every connection in the supply chain represents a point of failure, the entire model shifts. Logistics becomes clinical execution. Stability becomes operational strategy. Quality becomes accountability.

This is not a challenge of incremental improvement. It is a structural redesign of how biopharma programs plan, validate, and execute the movement of irreplaceable therapies from manufacturing to patient.

This guide explores the core capabilities required to integrate logistics, supply chain design, stability, and CMC into a unified model that protects product integrity and patient safety.